Adaptimmune Therapeutics PLC (ADAPY): R&D Expense
Not updated since 2024-12-31. No annual report in US GAAP has been filed since. Companies that switch to IFRS reporting, as many foreign filers do, or stop filing are not updated here.
$149.06M
Year ended 2024-12-31
+10.3%
3-year compound annual growth
+8.9%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2024-12-31 | $149.06M | +17.8% | 2025-03-24, From 2024-01-01 |
| 2023-12-31 | $126.51M | -1.0% | 2025-03-24, From 2023-01-01 |
| 2022-12-31 | $127.73M | +15.0% | 2025-03-24, From 2022-01-01 |
| 2021-12-31 | $111.09M | +21.3% | 2024-03-06, From 2021-01-01 |
| 2020-12-31 | $91.57M | -6.1% | 2023-03-06, From 2020-01-01 |
| 2019-12-31 | $97.50M | -0.8% | 2022-03-14, From 2019-01-01 |
| 2018-12-31 | $98.27M | +12.5% | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | $87.39M | +37.0% | 2019-02-27, From 2017-01-01 |
| 2016-12-31 | $63.79M | n/a | 2019-02-27, From 2016-01-01 |
| No annual figure between 2015-06-30 and 2016-12-31. | |||
| 2015-06-30 | $24.14M | +152.1% | 2018-03-15, From 2014-07-01 |
| 2014-06-30 | $9.57M | n/a | 2017-03-13, From 2013-07-01 |